Colchicine Dosing in Pericarditis
For acute pericarditis, use colchicine 0.5 mg twice daily if body weight ≥70 kg or 0.5 mg once daily if <70 kg for 3 months; for recurrent pericarditis, use the same weight-based dosing but extend duration to at least 6 months. 1
Weight-Based Dosing Algorithm
Acute Pericarditis
- ≥70 kg: 0.5 mg twice daily for 3 months
- <70 kg: 0.5 mg once daily for 3 months
- No loading dose should be used 1
- Add colchicine on top of aspirin or NSAIDs, not as monotherapy 1
Recurrent Pericarditis
- ≥70 kg: 0.5 mg twice daily for ≥6 months
- <70 kg: 0.5 mg once daily for ≥6 months
- Consider longer duration (>6 months) based on clinical response 1
The 2015 ESC Guidelines provide Class I, Level A recommendations for colchicine as first-line adjunctive therapy in both acute and recurrent pericarditis 1. This weight-based approach without loading doses improves compliance and reduces gastrointestinal side effects, which occur in approximately 8-10% of patients 2, 3.
Tapering Strategy
Tapering is not mandatory but may be considered in the final weeks of therapy 1:
- <70 kg: Reduce to 0.5 mg every other day
- ≥70 kg: Reduce to 0.5 mg once daily
When tapering multiple medications, stop one drug class at a time, with colchicine being discontinued last (over several months in difficult cases) 1. Only attempt tapering when symptoms have resolved and CRP has normalized 1.
Dose Adjustments for Renal Impairment
Mild to Moderate Renal Impairment (CrCl 30-80 mL/min)
- No dose adjustment required for standard regimens
- Monitor closely for adverse effects 4
Severe Renal Impairment (CrCl <30 mL/min)
- Start with 0.3 mg once daily
- Any dose increase requires close monitoring 4
Dialysis Patients
- 0.3 mg twice weekly for prophylaxis
- Monitor closely for toxicity 4
Recent evidence from 2026 suggests that initial doses <0.6 mg daily in CKD patients improve tolerability without compromising efficacy, with fewer gastrointestinal adverse events (12.5% vs 39.6%) and less need for dose reduction 5.
Elderly Patients (≥80 Years)
Use 0.5 mg once daily regardless of weight in very elderly patients 6. A 2025 case series demonstrated that low-dose colchicine (0.5 mg once daily) for at least 3 months was effective and well-tolerated in patients ≥80 years with recurrent pericardial effusion, with no observed side effects 6. Monitor liver and kidney function closely during treatment.
Hepatic Impairment
Avoid colchicine in severe hepatic impairment. For mild to moderate hepatic dysfunction, use the lowest effective dose (0.3 mg once daily) and monitor closely 4. The FDA label specifically warns against combining colchicine with CYP3A4 or P-glycoprotein inhibitors in patients with hepatic impairment.
Critical Drug Interactions Requiring Dose Reduction
With Strong CYP3A4 Inhibitors (e.g., clarithromycin, ketoconazole)
- Reduce to maximum 0.3 mg once daily (or 0.6 mg total daily dose)
- Do NOT treat acute gout flares if already on prophylactic colchicine 4
With P-glycoprotein Inhibitors (cyclosporine, ranolazine)
- Reduce to 0.3 mg once daily for prophylaxis
- Fatal toxicity has been reported with cyclosporine 4
With Protease Inhibitors
- Reduce to 0.3 mg once daily for pericarditis treatment
- Contraindicated if concurrent renal or hepatic impairment 4
Common Pitfalls to Avoid
Do not use loading doses – This increases gastrointestinal intolerance without improving efficacy 1
Do not use colchicine as monotherapy – Always combine with aspirin or NSAIDs for pericarditis 1
Do not taper too quickly – Premature discontinuation increases recurrence risk; taper only when symptoms resolve and CRP normalizes 1
Do not ignore drug interactions – Combining colchicine with strong CYP3A4 or P-gp inhibitors without dose adjustment can cause fatal toxicity 4, 7
Do not use high doses in elderly or renally impaired patients – Start low (0.3 mg daily) and monitor closely 5, 6
Monitoring Parameters
- C-reactive protein (CRP): Guide treatment duration and assess response 1
- Symptoms: Continue therapy until complete resolution
- Liver and kidney function: Monitor regularly, especially in elderly and those with impairment 6
- Complete blood count: Watch for bone marrow suppression in chronic use 7
The narrow therapeutic window of colchicine demands vigilance, but when dosed appropriately with weight-based regimens and proper adjustments for renal function, age, and drug interactions, it significantly reduces recurrence rates (from 37.5% to 16.7% in acute pericarditis) with acceptable tolerability 8.